Stock 688139 QINGDAO HAIER BIOMEDICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Qingdao Haier Biomedical Co.,Ltd

Equities

688139

CNE100003P25

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
39.97 CNY +3.42% Intraday chart for Qingdao Haier Biomedical Co.,Ltd -0.03% -1.36%
Apr. 25 Qingdao Haier Biomedical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Tranche Update on Qingdao Haier Biomedical Co.,Ltd's Equity Buyback Plan announced on February 9, 2024. CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
QINGDAO HAIER BIOMEDICAL CO.,LTD Stock Qingdao Haier Biomedical Co.,Ltd
-1.36% 1.74B -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.03% 223B
B
DANAHER CORPORATION Stock Danaher Corporation
+13.59% 195B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+20.01% 144B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+30.83% 111B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.05% 65.01B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+15.38% 53.02B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+3.96% 50.45B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.37% 44.15B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+3.27% 36.45B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688139 Stock
  4. Ratings Qingdao Haier Biomedical Co.,Ltd